These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 8306452)
1. Determination of changes in serum lathosterol during treatment with simvastatin to evaluate the role of lathosterol as a parameter for whole body cholesterol synthesis. De Cuyper I; Wolthers BG; van Doormaal JJ; Wijnandts PN Clin Chim Acta; 1993 Oct; 219(1-2):123-30. PubMed ID: 8306452 [TBL] [Abstract][Full Text] [Related]
2. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. Kempen HJ; Glatz JF; Gevers Leuven JA; van der Voort HA; Katan MB J Lipid Res; 1988 Sep; 29(9):1149-55. PubMed ID: 3183524 [TBL] [Abstract][Full Text] [Related]
3. Use of cholesterol precursors to assess changes in cholesterol synthesis under non-steady-state conditions. Pfohl M; Naoumova RP; Kim KD; Thompson GR Eur J Clin Invest; 1998 Jun; 28(6):491-6. PubMed ID: 9693942 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Watts GF; Naoumova RP; Kelly JM; Riches FM; Croft KD; Thompson GR Am J Physiol; 1997 Sep; 273(3 Pt 1):E462-70. PubMed ID: 9316434 [TBL] [Abstract][Full Text] [Related]
5. Serum lathosterol levels in human subjects reflect changes in whole body cholesterol synthesis induced by lovastatin but not dietary cholesterol. Duane WC J Lipid Res; 1995 Feb; 36(2):343-8. PubMed ID: 7751822 [TBL] [Abstract][Full Text] [Related]
6. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. Chao Y; Chen JS; Hunt VM; Kuron GW; Karkas JD; Liou R; Alberts AW Eur J Clin Pharmacol; 1991; 40 Suppl 1():S11-4. PubMed ID: 2044637 [TBL] [Abstract][Full Text] [Related]
7. Urinary excretion of mevalonic acid as an indicator of cholesterol synthesis. Lindenthal B; Simatupang A; Dotti MT; Federico A; Lütjohann D; von Bergmann K J Lipid Res; 1996 Oct; 37(10):2193-201. PubMed ID: 8906596 [TBL] [Abstract][Full Text] [Related]
8. Quantitation of plasma mevalonic acid using gas chromatography-electron capture mass spectrometry. Scoppola A; Maher VM; Thompson GR; Rendell NB; Taylor GW J Lipid Res; 1991 Jun; 32(6):1057-60. PubMed ID: 1940620 [TBL] [Abstract][Full Text] [Related]
9. Gas chromatography analysis of serum cholesterol synthesis and absorption markers used to predict the efficacy of simvastatin in patients with coronary heart disease. Wu WF; Wang QH; Zhang T; Mi SH; Liu Y; Wang LY Clin Biochem; 2013 Aug; 46(12):993-998. PubMed ID: 23598259 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the use of serum lathosterol concentration to assess whole-body cholesterol synthesis in rabbits. Meijer GW; Van der Palen JG; De Vries H; Kempen HJ; Van der Voort HA; Van Zutphen LF; Beynen AC J Lipid Res; 1992 Feb; 33(2):281-6. PubMed ID: 1569379 [TBL] [Abstract][Full Text] [Related]
11. The influence of simvastatin on adrenal corticosteroid production and urinary mevalonate during adrenocorticotropin stimulation in patients with heterozygous familial hypercholesterolemia. Prihoda JS; Pappu AS; Smith FE; Illingworth DR J Clin Endocrinol Metab; 1991 Mar; 72(3):567-74. PubMed ID: 1847705 [TBL] [Abstract][Full Text] [Related]
12. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes. Qin W; Infante J; Wang SR; Infante R Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634 [TBL] [Abstract][Full Text] [Related]
13. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Harrison RW; Ashton CH Br J Clin Pharmacol; 1994 Mar; 37(3):231-6. PubMed ID: 8198930 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Nègre-Aminou P; van Vliet AK; van Erck M; van Thiel GC; van Leeuwen RE; Cohen LH Biochim Biophys Acta; 1997 Apr; 1345(3):259-68. PubMed ID: 9150246 [TBL] [Abstract][Full Text] [Related]
15. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis. Alberts AW Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667 [TBL] [Abstract][Full Text] [Related]
16. The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Human JA; Ubbink JB; Jerling JJ; Delport R; Vermaak WJ; Vorster HH; Lagendijk J; Potgieter HC Clin Chim Acta; 1997 Jul; 263(1):67-77. PubMed ID: 9247729 [TBL] [Abstract][Full Text] [Related]
17. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia. Pappu AS; Bacon SP; Illingworth DR J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170 [TBL] [Abstract][Full Text] [Related]
18. Cholesterol biosynthesis in normocholesterolemic patients after cholesterol removal by plasmapheresis. Feillet C; Cristol JP; Michel F; Kanouni T; Navarro R; Navarro M; Monnier L; Descomps B J Clin Apher; 1997; 12(3):110-5. PubMed ID: 9365862 [TBL] [Abstract][Full Text] [Related]
19. Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia. Smit JW; Van Erpecum KJ; Portincasa P; Renooij W; Erkelens DW; Van Berge-Henegouwen GP Gut; 1995 Nov; 37(5):654-9. PubMed ID: 8549941 [TBL] [Abstract][Full Text] [Related]